OMER:NSD-Omeros Corporation (USD)

EQUITY | Biotechnology | NASDAQ Global Market

Last Closing

USD 10.84

Change

-0.37 (-3.30)%

Market Cap

USD 0.53B

Volume

0.61M

Analyst Target

USD 35.60
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Omeros Corp is engaged in the discovery, development and commercialization of pharmaceutical products for inflammation, coagulopathies and disorders of the central nervous system.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-06 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+5.83 (+1.45%)

USD 104.84B
REGN Regeneron Pharmaceuticals Inc

+14.04 (+1.96%)

USD 78.92B
ARGX argenx NV ADR

+3.25 (+0.50%)

USD 36.54B
ALNY Alnylam Pharmaceuticals Inc

+2.80 (+1.20%)

USD 30.22B
MRNA Moderna Inc

+4.96 (+11.65%)

USD 16.10B
UTHR United Therapeutics Corporatio..

+6.94 (+1.95%)

USD 15.91B
RPRX Royalty Pharma Plc

+0.29 (+1.13%)

USD 15.05B
SMMT Summit Therapeutics PLC

+0.69 (+3.95%)

USD 13.43B
INCY Incyte Corporation

+1.28 (+1.78%)

USD 13.41B
BMRN Biomarin Pharmaceutical Inc

+0.83 (+1.24%)

USD 12.74B

ETFs Containing OMER

BBC Virtus LifeSci Biotech Cl.. 0.99 % 0.79 %

-0.06 (-1.16%)

USD 8.55M
QQQS Invesco NASDAQ Future Gen.. 0.64 % 0.00 %

-0.35 (-1.16%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9.72% 68% D+ 82% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.72% 68% D+ 82% B
Trailing 12 Months  
Capital Gain 203.64% 96% N/A 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 203.64% 96% N/A 96% N/A
Trailing 5 Years  
Capital Gain -18.92% 70% C- 40% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -18.92% 69% C- 35% F
Average Annual (5 Year Horizon)  
Capital Gain 1.55% 50% F 43% F
Dividend Return 1.55% 50% F 38% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 86.92% 41% F 24% F
Risk Adjusted Return 1.79% 49% F 35% F
Market Capitalization 0.53B 77% C+ 66% D+

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 1.33 66% 91%
Price/Book Ratio 8.44 18% 16%
Price / Cash Flow Ratio 9.06 6% 31%
Price/Free Cash Flow Ratio -1.49 57% 73%
Management Effectiveness  
Return on Equity -576.33% 13% 6%
Return on Invested Capital -57.14% 51% 21%
Return on Assets -26.87% 60% 20%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.